Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.31
Q's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 0.31 )
Q' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 0.31

Equity to Asset -0.21
Q's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: -0.21 )
Q' s 10-Year Equity to Asset Range
Min: -0.55   Max: -0.18
Current: -0.21

-0.55
-0.18
Interest Coverage 3.74
Q's Interest Coverage is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 3.74 )
Q' s 10-Year Interest Coverage Range
Min: 2.79   Max: 3.74
Current: 3.74

2.79
3.74
Z-Score: 3.07
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 9.07
Q's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 9.07 )
Q' s 10-Year Operating margin (%) Range
Min: 7.98   Max: 10.07
Current: 9.07

7.98
10.07
Net-margin (%) 4.44
Q's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 4.44 )
Q' s 10-Year Net-margin (%) Range
Min: 3.65   Max: 5.59
Current: 4.44

3.65
5.59
ROA (%) 7.39
Q's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 7.39 )
Q' s 10-Year ROA (%) Range
Min: 7.1   Max: 10.41
Current: 7.39

7.1
10.41
ROC (Joel Greenblatt) (%) 231.66
Q's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 231.66 )
Q' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 185.85   Max: 231.66
Current: 231.66

185.85
231.66
» Q's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

Q Guru Trades in Q3 2013

Vanguard Health Care Fund 1,239,166 sh (+43.4%)
Ron Baron 326,729 sh (+18.07%)
Paul Tudor Jones Sold Out
Steven Cohen 4,780 sh (-60.26%)
» More
Q4 2013

Q Guru Trades in Q4 2013

Jim Simons 192,900 sh (New)
Joel Greenblatt 4,324 sh (New)
Caxton Associates 53,369 sh (New)
Vanguard Health Care Fund 3,636,278 sh (+193.45%)
Steven Cohen 9,344 sh (+95.48%)
Ron Baron 251,929 sh (-22.89%)
» More
Q1 2014

Q Guru Trades in Q1 2014

Paul Tudor Jones 17,916 sh (New)
Joel Greenblatt 17,666 sh (+308.56%)
Steven Cohen 30,923 sh (+230.94%)
Jim Simons 451,300 sh (+133.96%)
Ron Baron 327,309 sh (+29.92%)
Vanguard Health Care Fund 4,686,278 sh (+28.88%)
Caxton Associates 5,000 sh (-90.63%)
» More
Q2 2014

Q Guru Trades in Q2 2014

Ron Baron 402,309 sh (+22.91%)
Vanguard Health Care Fund 5,636,278 sh (+20.27%)
Steven Cohen 11,300 sh (unchged)
Caxton Associates Sold Out
Jim Simons 433,100 sh (-4.03%)
Paul Tudor Jones 12,942 sh (-27.76%)
Joel Greenblatt 7,008 sh (-60.33%)
» More
» Details

Insider Trades

Latest Guru Trades with Q

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-06-30 Add 20.27%0.13%$46.75 - $53.33 $ 56.7613%5636278
Ron Baron 2014-06-30 Add 22.91%0.02%$46.75 - $53.33 $ 56.7613%402309
Joel Greenblatt 2014-06-30 Reduce -60.33%0.01%$46.75 - $53.33 $ 56.7613%7008
Vanguard Health Care Fund 2014-03-31 Add 28.88%0.15%$45.8 - $54.94 $ 56.7613%4686278
Ron Baron 2014-03-31 Add 29.92%0.02%$45.8 - $54.94 $ 56.7613%327309
Joel Greenblatt 2014-03-31 Add 308.56%0.01%$45.8 - $54.94 $ 56.7613%17666
Vanguard Health Care Fund 2013-12-31 Add 193.45%0.34%$41.58 - $46.48 $ 56.7630%3636278
Ron Baron 2013-12-31 Reduce -22.89%0.02%$41.58 - $46.48 $ 56.7630%251929
Joel Greenblatt 2013-12-31 New Buy$41.58 - $46.48 $ 56.7630%4324
Vanguard Health Care Fund 2013-09-30 Add 43.4%0.06%$42.82 - $46.29 $ 56.7628%1239166
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Quintiles Transnational Holdings Inc

Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO
According to GuruFocus list of three-year lows; Teradata Corporation, Quintiles Transnational Holdings Inc., Grana y Montero SAA and EXCO Resources Inc. have all reached their three-year lows. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.90
Q's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 23.90 )
Q' s 10-Year P/E(ttm) Range
Min: 21.79   Max: 31.56
Current: 23.9

21.79
31.56
P/S 1.40
Q's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 1.40 )
Q' s 10-Year P/S Range
Min: 1.02   Max: 1.45
Current: 1.4

1.02
1.45
PFCF 20.60
Q's PFCF is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 20.60 )
Q' s 10-Year PFCF Range
Min: 18.77   Max: 35.38
Current: 20.6

18.77
35.38
EV-to-EBIT 16.20
Q's EV-to-EBIT is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 16.20 )
Q' s 10-Year EV-to-EBIT Range
Min: 14.8   Max: 18.3
Current: 16.2

14.8
18.3
Current Ratio 1.38
Q's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 1.38 )
Q' s 10-Year Current Ratio Range
Min: 1.15   Max: 1.42
Current: 1.38

1.15
1.42
Quick Ratio 1.38
Q's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 1.38 )
Q' s 10-Year Quick Ratio Range
Min: 1.15   Max: 1.42
Current: 1.38

1.15
1.42

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.21
Q's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 1.21 )
Q' s 10-Year Price/Median PS Value Range
Min: 0.86   Max: 1.11
Current: 1.21

0.86
1.11
Earnings Yield (Greenblatt) 6.20
Q's Earnings Yield (Greenblatt) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. Q: 6.20 )
Q' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.5   Max: 6.8
Current: 6.2

5.5
6.8

Business Description

Industry: »
Compare: » details
Traded in other countries:QTS.Germany
Quintiles Transnational Holdings Inc, provides biopharmaceutical development services and commercial outsourcing services. It operates in two segments namely Product Development segment and Integrated Healthcare Services segment. Product Development segment is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. The market served by Product Development segment consists of biopharmaceutical companies, including medical device and diagnostics companies that are seeking to outsource clinical trials and other product development activities. Integrated Healthcare Services segment includes commercial pharmaceutical sales and service organizations. It provides services including commercial services such as providing contract pharmaceutical sales forces, as well as growing number of healthcare business services for the broader healthcare sector. Integrated Healthcare Services segment addresses markets related to the use of approved pharmaceutical products. The Company competes against traditional CROs, the in-house R&D departments of biopharmaceutical companies, universities and teaching hospitals. Product Development's primary competitors include Covance, Inc., Pharmaceutical Product Development, Inc., PAREXEL International Corporation, ICON plc, inVentiv Health, Inc., or inVentiv, INC Research and PRA International. Integrated Healthcare Services' primary competitors in the United States include inVentiv, PDI, Inc. and Publicis Selling Solutions. Outside of the United States, Integrated Healthcare Services typically competes against single country or more regionally focused commercial service providers, such as United Drug plc, inVentiv, EPS Corporation and CMIC HOLDINGS Co., Ltd in Japan.
» More Articles for Q

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: TDC, Q, GRAM, XCO Dec 09 2013 
Vanguard Health Care Fund Gains 27%, Buys 4 New Stocks Jul 31 2013 
AT&T Inc. (T) Dividend Stock Analysis Jan 27 2011 
Stocks Jim Simons Keeps on Buying: CL, Q, LMT, NVO, HRB Jan 25 2011 
CenturyLink, Inc. – A Qwest for Growth Nov 22 2010 
Which S&P 500 Company Has the Shakiest Dividend: AT&T, Pepco, Qwest, CenturyTel, Diamond Offshore May 17 2010 
Qwest to Webcast Third Quarter 2009 Earnings Conference Call Sep 03 2009 
Qwest Reports Second Quarter 2009 Results Jul 29 2009 
Qwest Reports Fourth Quarter and Full Year 2008 Results Feb 10 2009 
Qwest Communications Announces Tax Treatment for 2008 Dividends Jan 19 2009 

More From Our Partners
Covance Retains Balanced View on Steady Growth - Analyst Blog Aug 22 2014 - ZACKS

More From Other Websites
Contract Researcher Parexel Sees Growth In Biotech Aug 21 2014
Quintiles CEO to Present at the Morgan Stanley Global Healthcare Conference Aug 20 2014
Quintiles CEO to Present at the Morgan Stanley Global Healthcare Conference Aug 20 2014
Expression Analysis Announces 2014 Grant Program Aug 19 2014
Expression Analysis Announces 2014 Grant Program Aug 19 2014
Encore Named One of Modern Healthcare's Best Places to Work in Healthcare for Fifth Year-In-A-Row Aug 18 2014
What's on Cramer's radar as Russia rattles bulls? Aug 15 2014
Jim Cramer's Top Stock Picks: YELP TPH Q Aug 14 2014
Jim Cramer's 'Mad Money' Recap: Now That's More Like It Aug 13 2014
Cramer: New IPO shows long-term promise Aug 13 2014
QUINTILES TRANSNATIONAL HOLDINGS INC. Financials Aug 08 2014
Will BioDelivery Sciences (BDSI) Disappoint this Earnings? Aug 06 2014
Dr. Phillip P. Chan, the CEO and President of CytoSorbents Corporation (CTSO), Interviews with The... Aug 01 2014
UPDATE: Deutsche Bank Reiterates On Quintiles Transnational On Mixed Factors Aug 01 2014
ICON plc (ICLR) Worth Watching: Stock Rises 8.8% Jul 31 2014
Q2 2014 Quintiles Transnational Holdings Inc Earnings Release - Before Market Open Jul 31 2014
Quintiles Reports 2nd Quarter 2014 Results Jul 31 2014
QUINTILES TRANSNATIONAL HOLDINGS INC. Files SEC form 8-K, Results of Operations and Financial... Jul 31 2014
Quintiles Reports 2nd Quarter 2014 Results Jul 31 2014
Quintiles Named Britain’s Healthiest Large Workplace Jul 21 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK